Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:26095365  

Integrated Genomics of Crohn's Disease Risk Variant Identifies a Role for CLEC12A in Antibacterial Autophagy.

Jakob Begun | Kara G Lassen | Humberto B Jijon | Leigh A Baxt | Gautam Goel | Robert J Heath | Aylwin Ng | Jenny M Tam | Szu-Yu Kuo | Eduardo J Villablanca | Lola Fagbami | Marije Oosting | Vinod Kumar | Monica Schenone | Steven A Carr | Leo A B Joosten | Jatin M Vyas | Mark J Daly | Mihai G Netea | Gordon D Brown | Cisca Wijmenga | Ramnik J Xavier
Cell reports | 2015

The polymorphism ATG16L1 T300A, associated with increased risk of Crohn's disease, impairs pathogen defense mechanisms including selective autophagy, but specific pathway interactions altered by the risk allele remain unknown. Here, we use perturbational profiling of human peripheral blood cells to reveal that CLEC12A is regulated in an ATG16L1-T300A-dependent manner. Antibacterial autophagy is impaired in CLEC12A-deficient cells, and this effect is exacerbated in the presence of the ATG16L1(∗)300A risk allele. Clec12a(-/-) mice are more susceptible to Salmonella infection, supporting a role for CLEC12A in antibacterial defense pathways in vivo. CLEC12A is recruited to sites of bacterial entry, bacteria-autophagosome complexes, and sites of sterile membrane damage. Integrated genomics identified a functional interaction between CLEC12A and an E3-ubiquitin ligase complex that functions in antibacterial autophagy. These data identify CLEC12A as early adaptor molecule for antibacterial autophagy and highlight perturbational profiling as a method to elucidate defense pathways in complex genetic disease.

Pubmed ID: 26095365

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: R01 AI097519
  • Agency: Wellcome Trust, United Kingdom
  • Agency: European Research Council, International
    Id: 310372
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI092084
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK097485
  • Agency: NIAID NIH HHS, United States
    Id: U19 AI109725
  • Agency: Wellcome Trust, United Kingdom
    Id: 102705
  • Agency: European Research Council, International
    Id: 322698
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK043351
  • Agency: NIAID NIH HHS, United States
    Id: AI109725
  • Agency: Wellcome Trust, United Kingdom
    Id: 102705/Z/13/Z
  • Agency: NIDDK NIH HHS, United States
    Id: DK097485
  • Agency: Wellcome Trust, United Kingdom
    Id: 084428

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


HeLa (tool)

RRID:CVCL_0030

Cell line HeLa is a Cancer cell line with a species of origin Homo sapiens

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions